Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 5/20 | 0.56 |
| ▸ | ESR1 | P03372 | 7/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7529231 | 0.99 | EBP (0.57) | EBPSIGMAR1LTA4HESR1HRH3 | |
| SCHEMBL13897747 | 0.90 | EBP (0.66) | EBPSIGMAR1LTA4HESR1HRH3 | |
| SCHEMBL7110375 | 0.90 | EBP (0.56) | EBPSIGMAR1LTA4HESR1HRH3 | |
| SCHEMBL13897766 | 0.90 | EBP (0.65) | EBPSIGMAR1LTA4HESR1HRH3 | |
| SCHEMBL7524285 | 0.90 | EBP (0.65) | EBPSIGMAR1LTA4HESR1HRH3 | |
| SCHEMBL3975634 | 0.89 | EBP (0.72) | EBPSIGMAR1LTA4HESR1HRH3 | |
| SCHEMBL9055095 | 0.89 | LTA4H (0.56) | EBPSIGMAR1LTA4HESR1HRH3 | |
| SCHEMBL7521111 | 0.88 | EBP (0.70) | EBPSIGMAR1LTA4HESR1HRH3 | |
| SCHEMBL7110262 | 0.85 | LTA4H (0.57) | EBPSIGMAR1LTA4HESR1HRH3 | |
| SCHEMBL3869661 | 0.85 | EBP (0.58) | EBPSIGMAR1ESR1HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501441-B1 | Naphthyl compounds, intermediates, processes, compositions, and methods | ELI LILLY AND COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501441-B1 | Naphthyl compounds, intermediates, processes, compositions, and methods | ELI LILLY AND COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501441-B1 | Naphthyl compounds, intermediates, processes, compositions, and methods | ELI LILLY AND COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-6437137-B1 | REDUCING (NAPHTHALEN-1-YL)(4-(2-(1-PIPERDINYL)ETHOXY) PHENYL)METHANONE WITH A REDUCING AGENT IN THE PRESENCE OF A SOLVENT, HEATING TO REFLUX; FORMING (NAPHTHALEN-1-YL)(4-(2-(1-PIPERDINYL)ETHOXY)PHENYL)METHANE | ELI LILLY AND COMPANY | 2002-08-20 | — | — | US | disclosed |
| EP-0702961-B1 | Compositions for minimizing the uterotrophic effect of tamoxifen and its analogs | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6410564-B1 | Naphthyl compounds, intermediates, processes, compositions, and methods | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| EP-0832883-B1 | Tetrahydrobenzo(a)fluorene compounds and methods of use | LILLY CO ELI (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-0703228-B1 | Naphthyl compounds, intermediates, processes, compositions involving them | LILLY CO ELI (US) | 2002-03-06 | — | — | EP | disclosed |
| US-5821253-A | INHIBIT BONE LOSS OR RESORPTION, LOWER SERUM CHOLESTEROL LEVELS | ELI LILLY AND COMPANY (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0832883-A1 | Tetrahydrobenzo(a)fluorene compounds and methods of use | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5554628-A | A 1-(4-ALKOXYPHENYL-)NAPHTHALENE COMPOUND | ELI LILLY AND COMPANY (US) | 1996-09-10 | — | — | US | disclosed |
| WO-1996009051-A1 | A METHOD FOR MINIMIZING THE UTEROTROPHIC EFFECT OF TAMOXIFEN AND TAMOXIFEN ANALOGS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| WO-1996009052-A1 | A METHOD FOR INHIBITING MAMMALIAN BREAST CARCINOMA WITH TAMOXIFEN, AND ANALOGS THEREOF, AND CERTAIN NAPHTHYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| WO-1996009039-A1 | NAPHTHYL COMPOUNDS, INTERMEDIATES, PROCESSES, COMPOSITIONS, AND METHODS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0702962-A2 | Preparations for inhibiting mammalian breast carcinoma with tamoxifen and analogs thereof, and certain naphthyl compounds | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0702961-A2 | Compositions for minimizing the uterotrophic effect of tamoxifen and its analogs | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0703228-A1 | Naphthyl compounds, intermediates, processes, compositions involving them | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
| US-5484796-A | Naphthyl compounds, intermediates, processes, compositions, and method of inhibiting aortal smooth muscle cell proliferation | ELI LILLY AND COMPANY (US) | 1996-01-16 | — | — | US | disclosed |
| US-5484795-A | Naphthyl compounds, intermediates, processes, compositions, and method of inhibiting restenosis | ELI LILLY AND COMPANY (US) | 1996-01-16 | — | — | US | disclosed |
| US-5484797-A | Naphthly compounds, intermediates, processes, compositions, and method for inhibiting endometrosis | ELI LILLY AND COMPANY (US) | 1996-01-16 | — | — | US | disclosed |